- Home
- TXNM vs ADMA Comparison
TXNM vs ADMA Comparison
Compare TXNM & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXNM
- ADMA
- Stock Information
- Founded
- TXNM 1917
- ADMA 2004
- Country
- TXNM United States
- ADMA United States
- Employees
- TXNM N/A
- ADMA N/A
- Industry
- TXNM
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TXNM
- ADMA Health Care
- Exchange
- TXNM NYSE
- ADMA Nasdaq
- Market Cap
- TXNM 4.9B
- ADMA 5.1B
- IPO Year
- TXNM N/A
- ADMA N/A
- Fundamental
- Price
- TXNM $56.43
- ADMA $17.74
- Analyst Decision
- TXNM Buy
- ADMA Strong Buy
- Analyst Count
- TXNM 7
- ADMA 4
- Target Price
- TXNM $54.86
- ADMA $24.25
- AVG Volume (30 Days)
- TXNM 1.4M
- ADMA 2.9M
- Earning Date
- TXNM 07-30-2025
- ADMA 08-07-2025
- Dividend Yield
- TXNM 2.89%
- ADMA N/A
- EPS Growth
- TXNM 144.40
- ADMA N/A
- EPS
- TXNM 2.24
- ADMA 0.84
- Revenue
- TXNM $2,017,114,000.00
- ADMA $459,381,000.00
- Revenue This Year
- TXNM $10.59
- ADMA $23.35
- Revenue Next Year
- TXNM $5.09
- ADMA $27.67
- P/E Ratio
- TXNM $25.23
- ADMA $21.23
- Revenue Growth
- TXNM 10.11
- ADMA 62.23
- 52 Week Low
- TXNM $35.56
- ADMA $10.21
- 52 Week High
- TXNM $57.29
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- TXNM 57.98
- ADMA 32.83
- Support Level
- TXNM $56.46
- ADMA $20.42
- Resistance Level
- TXNM $56.87
- ADMA $22.37
- Average True Range (ATR)
- TXNM 0.35
- ADMA 0.88
- MACD
- TXNM -0.16
- ADMA -0.28
- Stochastic Oscillator
- TXNM 18.06
- ADMA 1.07
About TXNM TXNM ENERGY INC
TXNM Energy Inc is a holding company that owns regulated utility companies providing energy to houses and businesses across Texas and New Mexico using its utilities.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.